FDA gives green light to trial of HBV treatment GIGA-2339
The U.S. Food and Drug Administration (FDA) has given Gigagen the go-ahead to start clinical testing of GIGA-2339, its experimental treatment for hepatitis B…
News
CM-101 shows signs of targeting all PSC aspects in Phase 2 trial
The experimental therapy CM-101 is generally safe and results in signs of improvement in liver health and health of the ducts that transport the…
PFIC treatment IN016 gets FDA orphan drug status
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IN016, an experimental therapy Innorna is developing for progressive familial…
Pemvidutide seen to lower liver fat in MASLD patients in Phase 1 trial
Pemvidutide, Altimmune’s experimental therapy, significantly reduced liver fat and inflammation, as well as body weight, among overweight or obese people with metabolic dysfunction-associated…
Study identifies predictor of serious liver complication in biliary atresia
Having persistently high blood levels of bilirubin, a marker of liver damage, a year after undergoing a corrective liver surgery called the Kasai procedure increases…
CDA Foundation grants aim to help US hepatitis patients find doctors
In its efforts to connect diagnosed but untreated hepatitis B or C patients with physicians, the Center for Disease Analysis (CDA) Foundation has…
EMA committee recommends Iqirvo approval for PBC in Europe
A European Medicines Agency (EMA) committee has recommended the approval of Ipsen‘s Iqirvo (elafibranor) as a second-line therapy for adults with primary biliary…
Blood biomarkers may aid newborn cholestasis diagnosis: Study
Measuring blood levels of bile acids, a component of bile, and the gamma-glutamyl transferase (GGT) enzyme may aid newborn cholestasis diagnosis by distinguishing between…
Poor sleep quality ID’d as key risk factor for fatty liver disease
Poor sleep quality — noted by researchers as increasingly common in modern society — is significantly linked to a higher chance of having metabolic dysfunction-associated…
Dupilumab works as itching treatment in Alagille case: Report
The use of dupilumab, an approved anti-inflammatory antibody-based treatment, worked to ease itching, known medically as pruritus, in a young woman with Alagille syndrome…
Recent Posts
- Biliary atresia patient spotlighted in 2025 ALF Liver Life Walk
- How I advocated for my brother before and after his PSC diagnosis
- Researchers uncover how hepatitis B virus can persist in liver cells
- CM-101 (nebokitug) set for primary sclerosing cholangitis Phase 3 trial
- Researchers develop tool to predict drug-induced cholestasis